openPR Logo
Press release

Cardiac Biomarkers Testing Market to Reach $18,232 Million, By Growing at a CAGR of 11.4% from 2019 to 2026 with Top Players are Roche Diagnostics, Abbott Laboratories, Siemens Healthcare, Becton.

06-19-2019 09:52 AM CET | Health & Medicine

Press release from: Allied Market Research

Cardiac Biomarkers Testing Market

Cardiac Biomarkers Testing Market

The global cardiac biomarkers testing market size generated $7,638 million in 2018, and is projected to reach $18,232 million by 2026, growing at a CAGR of 11.4% from 2019 to 2026. The cardiac troponins segment, both T and I, forefronts among all other cardiac biomarker types, holding the largest share due to its strong performance, as cardiac troponins are the most sensitive and specific biomarkers for subsequent events of myocardium injury.

Download Report Sample @ https://www.alliedmarketresearch.com/request-sample/5284

The global cardiac biomarkers testing market has witnessed significant growth in the past few years, and is anticipated to continue to grow at a consistent pace, due to high prevalence of cardiac diseases that widely remain undiagnosed. Large number of cardiac biomarkers in pipeline, augmented patient awareness toward the importance of early detection of cardiovascular diseases, and opportunities in untapped countries such as India, China, and other Asia-Pacific countries are the key factors that contribute toward the growth of the market. In addition, introduction of novel cardiac biomarkers for point of care (POC) testing and facilitating quick results for chronic patients serve as opportunistic approaches to drive the market growth. However, premium pricing of approved and novel single used cardiac biomarkers and uncertain government regulation regarding the approval for biomarker tests and assays are expected to hinder the market growth during the analysis period.

Presence of large undiagnosed patient population, rise in incidence of cardiovascular diseases (CVDs), rapid urbanization, increase in disposable income, improved government funding toward healthcare, and surge in awareness about cardiac events, i.e., quick checkups after the onset of chest pain are the prime reasons responsible for the market growth in North America. Furthermore, the market growth is driven by novel progress in the treatments with improved overall survival benefits using multi-assay biomarkers. The survival benefit would be influential in governing the peak sales and market penetration of novel approved cardiac biomarker-based devices.

Buy Now @ https://www.alliedmarketresearch.com/checkout-final/d6b9ef3945655d3d1baf0bc92f35df8c

The Major Key Players Are:

• Roche Diagnostics
• Abbott Laboratories
• Siemens Healthcare
• Becton
• Dickinson and Company
• Bio-Rad Laboratories
• BioMerieux
• PerkinElmer Inc.
• Tosoh Corporation
• Danaher Corporation
• Thermo Fisher Scientific.

Based on cardiac biomarker type, the market is segmented into creatine kinase (CK-MB), troponins T and I, myoglobin, BNPs, IMA, and others. The IMA segment is expected to grow at high CAGR, as these biomarkers improve the sensitivity and negative predictive value for the diagnosis of myocardial ischemia when used in combination with standard cardiac biomarkers.

The applications covered in the study include myocardial infarction, congestive heart failure, acute coronary syndrome, atherosclerosis, and others. The congestive heart failure segment is expected to register the highest growth rate, owing to increased demand for biomarker tests for early detection of heart failure.

Read More Info @ https://www.prnewswire.com/news-releases/cardiac-biomarkers-testing-market-to-reach-18-23-bn-globally-by-2026-at-11-4-cagr-allied-market-research-300867061.html

North America led the global market in 2018, due to high demand for cardiac testing, increase in prevalence rate of CVD, and rise in awareness toward cardiac diagnostics solutions. Moreover, intensive efforts taken by government and research institutes to deal with critical cardiac diseases and increase in R&D activities related to cardiac biomarkers are expected to boost the market growth in North America.

Key Findings of the Cardiac Biomarkers Testing Market:

• By type, the troponin segment is projected to dominate the market during the forecast period.
• The myocardial infarction segment is expected to grow more than twofold during the forecast period.
• Laboratory testing market is expected to garner XX of the overall market revenue by 2026
• Based on location of testing segment, the point of care cardiac biomarker testing segment is projected to grow at a CAGR of XX% throughout the forecast period.
• Asia-Pacific region holds immense future market potential as there is a higher count of undiagnosed Cardiac patients diagnosed precisely

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: www.alliedmarketresearch.com

About Us:

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.

Allied Market Research provides one stop solution from the beginning of data collection to investment advice. The analysts at Allied Market Research dig out factors that help clients to understand the significance and impact of market dynamics. The company amplies client’s insight on the factors, such as strategies, future estimations, growth or fall forecasting, opportunity analysis, and consumer surveys among others. As follows, the company offers consistent business intelligent support to aid the clients to turn into prominent business firm.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Cardiac Biomarkers Testing Market to Reach $18,232 Million, By Growing at a CAGR of 11.4% from 2019 to 2026 with Top Players are Roche Diagnostics, Abbott Laboratories, Siemens Healthcare, Becton. here

News-ID: 1780564 • Views: 643

More Releases from Allied Market Research

North America Geogrid Market 2020 Segmentation, Demand, Growth, Trend, Opportuni …
According to the report published by Allied Market Research, the North America geogrid market generated $282.0 million in 2019, and is estimated to reach $408.25 million by 2027, registering a CAGR of 7.0% from 2020 to 2027. The report offers an extensive analysis of changing market dynamics, key winning strategies, business performance, major segments, and competitive scenarios. Surge in infrastructure development activities across the U.S. and Mexico and superior physical properties
Intravenous Immunoglobulin (IVIG) Market 2020 In-Depth Analysis of Industry Shar …
Global intravenous immunoglobulin market accounted for $8,995 million in 2017, and is projected to reach $15,964 million by 2025, registering a CAGR of 7.5% from 2018 to 2025. Immunoglobulin (Ig) is a plasma-derived product, which is obtained from the serum of healthy donors. The isolated plasma product is clinically treated and purified to Ig, which can be further used in the treatment of patients with antibody deficiency. Intravenous immunoglobulin (IVIG) finds
Asthma and COPD Drugs Market Is Expected to Witness a Steady Growth by 2026
"Asthma and COPD Drugs Market by Disease and Medication Class - Global Opportunity Analysis and Industry Forecasts, 2014-2022", projects that the global market for Asthma and COPD Drugs was valued at $38,960 million in 2015 and would reach $50,359 million by 2022, registering a CAGR of 3.7% from 2016 to 2022. Asthma segment dominated the market in 2015 and expected to continue its dominance throughout the forecast period. North America
Synthetic Biology Market in Global Industry by Top Companies, Type and Applicati …
Global Synthetic biology market is forecast to reach $38.7 billion by 2020, at a CAGR of 44.2% during the forecast period (2014 - 2020). Europe occupies largest share in the global market and would hold-on to its position throughout 2020. However, Asia Pacific is the fastest growing market with a CAGR of 46.4% from 2014 - 2020. Read Full Report @ https://www.alliedmarketresearch.com/synthetic-biology-market Synthetic biology is at a nascent stage and has recently

All 5 Releases


More Releases for Cardiac

Global Cardiac Monitoring & Cardiac Rhythm Management Market Insights, Forecast
Cardiac monitoring (CM) devices help in continuous examination of a patient’s cardiac activity. Cardiac rhythm management (CRM) devices maintain normal cardiac rhythm in patients suffering from rate and rhythm disorders of the heart. These devices play a crucial role in the treatment of serious cardiac disorders, including heart failure, atrial fibrillation, atrial flutter, indications of recent heart attack, coronary ischemia, lack of oxygen supply to cardiac muscles, effects of drugs,
Ambulatory Cardiac Monitoring Devices
Ambulatory Cardiac Monitoring Devices Market by Product (Ambulatory Rhythm Monitor, Ambulatory ECG Monitor, Ambulatory Cardiac Event Monitor, Implantable Loop Recorder, Ambulatory real-time Cardiac Monitors, Cardiac Output Monitors); by End-User (Hospitals, Ambulatory Care Centers); by Region (U.S., Rest of North America, France, UK, Germany, Spain, Italy, Rest of Europe, China, Japan, India, Southeast Asia, Rest of Asia Pacific, GCC Countries, Southern Africa, Rest of MEA, Brazil, Rest of Latin America) –
Cardiac Monitoring & Cardiac Rhythm Management Devices Market Stupendous Growth …
Cardiac Monitoring & Cardiac Rhythm Management Devices Market: Snapshot The global cardiac monitoring and cardiac rhythm management devices market is driven by growing incidences of cardiovascular diseases and growing private institutional home care and nursing. The technological advancements in the medical sector have helped develop innovative products and this is furthering the growth of the cardiac monitoring and cardiac rhythm management devices market. The rising treatment costs of cardiac diseases are
Mexico Cardiac Assist Devices
Mexico Cardiac Assist Devices Overview "Mexico Cardiac Assist Devices Market Outlook to 2025", provides key market data on the Mexico Cardiac Assist Devices market. The report provides value, in millions of US dollars, volume (in units) and average prices (USD) within market segments - Intra-Aortic Balloon Pumps, Total Artificial Heart and Ventricular Assist Devices. Click here for sample report @ https://www.wiseguyreports.com/sample-request/3107735-mexico-cardiac-assist-devices-market-outlook-to-2025   Major Key Players: Abbott Laboratories Medtronic plc Getinge AB. Major Highlight of the report: The report also provides
Cardiac Monitoring & Cardiac Rhythm Management Market Review and Forecast 2025
Crystalmarketresearch.com published “Cardiac Monitoring & Cardiac Rhythm Management Market By Component, Technology, Application, And End User - Global Industry Analysis And Forecast To 2025” from its database. The report reviews top companies involved and enlists all trials pertaining to the company. The cardiac monitoring & cardiac rhythm management market is expected to be worth $XX billion by 2025. The market is largely driven by factors such as rising incidence of cardiovascular
Cardiac Monitoring & Cardiac Rhythm Management Devices Market
Cardiac Monitoring & Cardiac Rhythm Management Devices Market: Snapshot The global cardiac monitoring and cardiac rhythm management devices market is driven by growing incidences of cardiovascular diseases and growing private institutional home care and nursing. The technological advancements in the medical sector have helped develop innovative products and this is furthering the growth of the cardiac monitoring and cardiac rhythm management devices market. The rising treatment costs of cardiac diseases are